Luxembourg-headquartered Covis is taking two COPD drugs off AstraZeneca’s hands in a US$270m deal.
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
German drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments.
Institut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers.
The French company has taken big steps to scale up its process for converting plant-based feedstocks into isobutene, bringing affordable aviation biofuels into reach.
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
With €600m from a directed share issue in its coffers, BICO finalises the acquisition of QInstruments, a specialist in advanced sample preparation automation.
The European Circular Bioeconomy Fund, initiated by the EU, has raised more than €200m that will be used to drive the transformation towards a bio-based economy.
Gerd Altmann/pixabay.comGerman CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Bad news for Swiss drug discovery company Idorsia: Its Fabry disease hopeful lucerastat failed to reduce neuropathic pain in patients.